SEC Filing Summary: Cyclacel Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K Current Report was filed by Cyclacel Pharmaceuticals, Inc. on July 6, 2016, covering the event date of July 1, 2016. The registrant is a Delaware corporation headquartered in Berkeley Heights, New Jersey. Note: The request metadata referenced "Bio Green Med Solution, Inc.," but the filing text explicitly identifies the registrant as Cyclacel Pharmaceuticals, Inc.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the departure of a director from the Board of Directors.
- Item 5.02: Nicholas Bacopoulos, Ph.D., notified the Company of his intention to retire for personal reasons.
- Effective Date: July 1, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the director's retirement.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the retirement of Nicholas Bacopoulos, Ph.D.
- Confirm whether a successor director has been appointed to fill the vacancy.
- Review subsequent filings for any financial updates, as this 8-K contains no financial data.